Brokerages Set Krystal Biotech, Inc. (NASDAQ:KRYS) Target Price at $220.00

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) have been given an average recommendation of "Buy" by the eight analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $220.00.

Several analysts have recently commented on the company. Citigroup increased their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. Jefferies Financial Group assumed coverage on Krystal Biotech in a report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target on the stock. Cantor Fitzgerald reissued an "overweight" rating and issued a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. Chardan Capital increased their target price on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. Finally, HC Wainwright reissued a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Friday, February 28th.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by insiders.

Remove Ads

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. FMR LLC grew its holdings in shares of Krystal Biotech by 0.5% during the fourth quarter. FMR LLC now owns 4,314,014 shares of the company's stock worth $675,833,000 after buying an additional 21,133 shares in the last quarter. Vanguard Group Inc. grew its stake in Krystal Biotech by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after purchasing an additional 28,707 shares in the last quarter. Avoro Capital Advisors LLC boosted its stake in shares of Krystal Biotech by 0.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock worth $411,831,000 after acquiring an additional 6,600 shares during the period. State Street Corp boosted its stake in shares of Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company's stock worth $264,455,000 after acquiring an additional 119,936 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Krystal Biotech by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company's stock worth $107,714,000 after acquiring an additional 11,411 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS traded down $0.57 during trading hours on Monday, reaching $188.61. The stock had a trading volume of 151,595 shares, compared to its average volume of 283,497. The business's fifty day moving average is $165.34 and its two-hundred day moving average is $173.69. The company has a market cap of $5.43 billion, a price-to-earnings ratio of 63.08 and a beta of 0.87. Krystal Biotech has a twelve month low of $141.72 and a twelve month high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $91.10 million during the quarter, compared to analyst estimates of $91.35 million. During the same period in the prior year, the company posted $0.30 earnings per share. Krystal Biotech's revenue was up 116.4% on a year-over-year basis. Sell-side analysts forecast that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).